ad image

Antisense Oligonucleotides

1 / 1
SynaptixBio
Rare Disease

Rare Disease Biotech Announces ‘Hugely Significant’ Milestone with Selection of Candidate Drug

SynaptixBio

PR-06-25-NI-02Jun 10, 2025
Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics
RNA

Beyond mRNA Vaccines: The Expanding World of RNA-Based Therapeutics

David Alvaro, Ph.D.

Pharma's Almanac

PAO-25-30-24Mar 21, 2025
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
Gene Tools

Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos

David Alvaro, Ph.D.; Jon Moulton, Ph.D.

Pharma's Almanac

PAO-01-23-CL-05Feb 01, 2023
Potential Applications for Antisense Oligonucleotide Therapies Continue to Expand
Column: New Drug Watch

Potential Applications for Antisense Oligonucleotide Therapies Continue to Expand

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-10-022-NI-06Oct 11, 2022
1 / 1